CNS biomarkers from blood
Brain-derived biomarkers from a routine blood draw
NeuroDex’s ExoSORT™ platform isolates extracellular vesicles released into blood by brain cells, such as neurons and oligodendrocytes, to measure target engagement, pharmacodynamics and disease biology. Every assay runs in our CLIA-certified, GCLP-aligned laboratories in Natick, MA, from preclinical studies through clinical trials.

Why brain-derived
Why measure biomarkers inside brain-derived vesicles?
Blood markers like NfL tell you the brain is injured, not whether your drug reached its target. Proteins such as α-synuclein and TDP-43 are made throughout the body, so a plain plasma reading mixes brain and non-brain signal. ExoSORT™ enriches the vesicles that brain cells, such as neurons and oligodendrocytes, release into blood, so the readout reflects brain biology.
Phase 2b
Trial-proven
Neuron-derived TDP-43 measured in our lab was a registered primary outcome in the PARADIGM ALS trial (NCT05357950).
>80%
Checked against CSF
Sensitivity and specificity of neuron-derived α-synuclein for predicting CSF seeding-assay positivity (N=150 PD and LBD).
500 µL
Built for trials
EDTA plasma per sample, with reports typically 2–3 weeks after receipt.
40+
Backed by the field
Pharma and biotech collaborations, with funding from the Michael J. Fox Foundation, ADDF and Target ALS.
Brain-derived biomarker panels for CNS drug development
Evidence
Funded, peer-reviewed and used in clinical trials
1,062+
Open dataset
Neuron-derived EV RNA-seq samples from about 356 PDBP participants, released in AMP PD Release 4.3.
About the dataset1,304
Autopsy-validated
With Columbia University: α-synuclein in neuron-derived vesicles was elevated in Lewy body pathology confirmed at autopsy.
Read the studyGLP-1
CNS target engagement
With Stanford: first evidence of CNS target engagement for GLP-1 and PPARγ agonists from blood (JCEM, 2026).
Read the study17
Peer-reviewed papers
Publications on brain-derived extracellular vesicles, from 2016 to 2026.
See publicationsBiomarker services for CNS drug development
NeuroDex works with pharma and biotech teams from target validation through clinical trials. Our brain-derived extracellular vesicle panels give your program target-engagement, pharmacodynamic and stratification readouts from plasma, with no lumbar puncture, run in our CLIA-certified, GCLP-aligned laboratory.
Target engagement
Pharmacodynamics
CLIA & GCLP quality
Patient stratification
Parkinson's disease and synucleinopathy
α-synuclein for stratification and target engagement in synucleinopathy programs.
ALS
TDP-43 for ALS and FTD programs, including a Phase 2b primary outcome.
Alzheimer's disease
Tau/pTau and synaptic markers for Alzheimer’s drug programs.
Neuroinflammation
NF-κB pathway activity for anti-inflammatory CNS programs.
Autophagy, Brain injury
LC3 and cathepsin D for autophagy–lysosome programs.




